SPRY
insider transactionsARS Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-28.4K
0 buy · 28.4K sell
Net value · 90d
-$283.6K
$0 in · $283.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
2
0 buy · 28.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Commercial Officer · 10b5-1
$0
25.0K sh
Own +5%
-
Sell·S
Chief Commercial Officer · 10b5-1
$250.0K
25.0K sh · $10.00
Own -67%
-
Exercise·M
Chief Commercial Officer · 10b5-1
$37.5K
25.0K sh · $1.50
Own +205%
-
Sell·S
Chief Legal Officer · 10b5-1
$33.5K
3.4K sh · $10.00
Own -4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Eric Karas 10b5-1 | Exercise M | 25.0K | $0 |
| Jun 12, 2026 | Eric Karas 10b5-1 | Sell S | 25.0K | $250.0K |
| Jun 12, 2026 | Eric Karas 10b5-1 | Exercise M | 25.0K | $37.5K |
| Jun 12, 2026 | Alexander A Fitzpatrick 10b5-1 | Sell S | 3.4K | $33.5K |
About SPRY insider trading
This page tracks insider transactions for ARS Pharmaceuticals, Inc. (SPRY) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.